Venous thromboembolism and cancer;Maladie veineuse thromboembolique et cancer

Revue de Medecine Interne

Volumn 27, Issue 4, 2006, Pages 313-322

  Pavic, M ^a   Debourdeau, P ^a   Aletti, M ^a   Farge Bancel, D ^b   Rousset, H ^c  

^a HIA Desgenettes   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Cancer; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADVANCED CANCER; ANAMNESIS; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CANCER; CANCER CHEMOTHERAPY; CATHETER; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; HUMAN; LABORATORY TEST; MEDIASTINUM MASS; PATHOPHYSIOLOGY; PERFUSION; PHYSICAL EXAMINATION; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; SCREENING; SHORT SURVEY; SURVIVAL; THORAX RADIOGRAPHY; TREATMENT DURATION; VENOUS STASIS; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; FORECASTING; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; THROMBOCYTE DISORDER; THROMBOEMBOLISM; TIME; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELET DISORDERS; CATHETERIZATION, CENTRAL VENOUS; FEMALE; FORECASTING; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PRIMARY PREVENTION; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; VENOUS THROMBOSIS;

EID: 33645890292     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.11.016     Document Type: Short Survey

References (88)

1. Nordstrom M., Lindblad B., Anderson H., Bergqvist D., and Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 308 (1994) 891-894
2. Cornuz J., Pearson S.D., Creager M.A., Cook E.F., and Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann. Intern. Med. 125 (1996) 785-793
3. Gore J.M., Appelbaum J.S., Greene H.L., Dexter L., and Dalen J.E. Occult cancer in patients with acute pulmonary embolism. Ann. Intern. Med. 96 (1982) 556-560
4. Goldberg R.J., Seneff M., Gore J.M., Anderson F.A., Greene H.L., Wheeler H.B., et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch. Intern. Med. 147 (1987) 251-253
5. Griffin M.R., Stanson A.W., Brown M.L., Hauser M.F., O'Fallon W.M., Anderson H.M., et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch. Intern. Med. 147 (1987) 1907-1911
6. Prandoni P., Lensing A.W., Buller H.R., Cogo A., Prins M.H., Cattelan A.M., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 327 (1992) 1128-1133
7. White R.H., Chew H.K., Zhou H., Parikh Patel A., Harris D., Harvey D., et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch. Intern Med. 165 (2005) 1782-1787
8. Sorensen H.T., Mellemkjaer L., Steffensen F.H., Olsen J.H., and Nielsen G.L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N. Engl. J. Med. 338 (1998) 1169-1173
9. Baron J.A., Gridley G., Weiderpass E., Nyren O., and Linet M. Venous thromboembolism and cancer. Lancet 351 (1998) 1077-1080
10. Lee A.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003) I17-I21
11. Piccioli A., Lensing A.W., Prins M.H., Falanga A., Scannapieco G.L., Leran M., et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J. Thromb. Haemost. 2 (2004) 884-889
12. Mandala M., Ferretti G., Cremonesi M., Cazzaniga M., Curigliano G., and Barni S. Venous thromboembolism and cancer: new issues for an old topic. Crit. Rev. Oncol. Hematol. 48 (2003) 65-80
13. Fennerty T. Screening for cancer in venous thromboembolic disease. BMJ 323 (2001) 704-705
14. Rance A., Emmerich J., Guedj C., and Fiessinger J.N. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 350 (1997) 1448-1449
15. Lee A.Y. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb. Res. 110 (2003) 167-172
16. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 160 (2000) 809-815
17. Thompson C.M., and Rodgers L.R. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am. J. Med. Sci. 223 (1952) 469-478
18. Sons H.U., Borchard F., and Joel B.S. Carcinoma of the gallbladder: autopsy findings in 287 cases and review of the literature. J. Surg. Oncol. 28 (1985) 199-206
19. Falanga A. Thrombosis and malignancy: an underestimated problem. Haematologica 88 (2003) 607-610
20. Svendsen E., and Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J. Clin. Pathol. 42 (1989) 805-809
21. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320 (1989) 479-484
22. Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D.L., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89 (1997) 1673-1682
23. Lee A.Y., and Levine M.N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost. 25 (1999) 137-145
24. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy vs those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
25. Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost. 78 (1997) 133-136
26. Sallah S., Wan J.Y., and Nguyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb. Haemost. 87 (2002) 575-579
27. Blom J.W., Doggen C.J., Osanto S., and Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
28. Thodiyil P.A., Walsh D.C., and Kakkar A.K. Thromboprophylaxis in the cancer patient. Acta Haematol. 106 (2001) 73-80
29. Piccioli A., Prandoni P., Ewenstein B.M., and Goldhaber S.Z. Cancer and venous thromboembolism. Am. Heart J. 132 (1996) 850-855
30. Hoffman R., Haim N., and Brenner B. Cancer and thrombosis revisited. Blood Rev. 15 (2001) 61-67
31. Nicolson G.L., and Custead S.E. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res. 45 (1985) 331-336
32. Lee A.Y. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat. Rev. 28 (2002) 137-140
33. Meyer G., Farge D., Sauvaget F., Diehl J.L., Hervé R., Rouffy J., et al. Maladie thromboembolique et cancer. Presse Med. 23 (1994) 1767-1771
34. Rogers II J.S., Murgo A.J., Fontana J.A., and Raich P.C. Chemotherapy for breast cancer decreases plasma protein C and protein S. J. Clin. Oncol. 6 (1988) 276-281
35. Kuzel T., Esparaz B., Green D., and Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65 (1990) 885-889
36. Mitchell L., Hoogendoorn H., Giles A.R., Vegh P., and Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood 83 (1994) 386-391
37. Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am. J. Med. 117 (2004) 508-515
38. Marx G.M., Steer C.B., Harper P., Pavlakis N., Rixe O., and Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J. Clin. Oncol. 20 (2002) 1446-1448
39. Levesque H., Belizna C., Michel P., and Pfister C. Traitement de la maladie thromboembolique veineuse chez les patients souffrant de cancers. Rev. Med. Intern. 25 (2004) 906-914
40. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van der Meer J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman study group. N. Engl. J. Med. 334 (1996) 682-687
41. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N. Engl. J. Med. 337 (1997) 657-662 (The Columbus Investigators)
42. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. 18 (2000) 3078-3083
43. Pini M., Aiello S., Manotti C., Pattacini C., Quintavalla R., Poli T., et al. Low molecular weight heparin vs warfarin in the prevention of recurrences after deep vein thrombosis. Thromb. Haemost. 72 (1994) 191-197
44. Das S.K., Cohen A.T., Edmondson R.A., Melissari E., and Kakkar V.V. Low-molecular-weight heparin vs warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J. Surg. 20 (1996) 521-526 (discussion 526-7)
45. Lopaciuk S., Bielska-Falda H., Noszczyk W., Bielawiec M., Witkiewicz W., Filipecki S., et al. Low molecular weight heparin vs acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb. Haemost. 81 (1999) 26-31
46. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomised-controlled study. Arch. Intern. Med. 162 (2002) 1729-1735
47. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin vs a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349 (2003) 146-153
48. Caine G.J., and Lip G.Y. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?. Arch. Intern. Med. 163 (2003) 1243-1244
49. Bura-Riviere A., and Fiessinger J.N. Les nouveaux anticoagulants dans la maladie thromboembolique veineuse. Rev. Med. Interne 24 (2003) 738-744
50. Schwarz R.E., Marrero A.M., Conlon K.C., and Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J. Clin. Oncol. 14 (1996) 652-657
51. Ihnat D.M., Mills J.L., Hughes J.D., Gentile A.T., Berman S.S., and Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?. J. Vasc. Surg. 28 (1998) 800-807
52. Streiff M.B. Vena caval filters: a comprehensive review. Blood 95 (2000) 3669-3677
53. Deitcher S.R. Cancer and thrombosis: mechanisms and treatment. J. Thromb. Thrombolysis 16 (2003) 21-31
54. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du risque d'embolie pulmonaire par interruption cave study group. N. Engl. J. Med. 338 (1998) 409-415
55. PREPIC study group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (prevention du risque d'embolie pulmonaire par interruption cave) randomized study. Circulation 112 (2005) 416-422
56. Levine M.N., Lee A.Y., and Kakkar A.K. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J. Thromb. Haemost. 1 (2003) 1456-1463
57. Kakkar A.K., and Williamson R.C. Prevention of venous thromboembolism in cancer patients. Semin. Thromb. Hemost. 25 (1999) 239-243
58. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 2 (1975) 45-51 (An international multicentre trial)
59. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., and Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br. J. Surg. 88 (2001) 913-930
60. Hull R.D., Pineo G.F., Stein P.D., Mah A.F., Maclsaac S.M., Dahl O.E., et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann. Intern. Med. 135 (2001) 858-869
61. Bergqvist D., Agnelli G., Cohen A.T., Eldor A., Nilsonn P.E., Le Moigne-Amrani A., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 346 (2002) 975-980
62. Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomised trial of a very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
63. Rajan R., Gafni A., Levine M., Hirsh J., and Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J. Clin. Oncol. 13 (1995) 42-46
64. Masci G., Magagnoli M., Zucali P.A., Castagna L., Carnaghi C., Sarina B., et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?. J. Clin. Oncol. 21 (2003) 736-739
65. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N. Engl. J. Med. 341 (1999) 793-800
66. Gratadou D., Elias A., Elias M., and Boccalon H. Thromboses veineuses sur cathéters centraux en cancérologie. Presse Med. 30 (2001) 298-301
67. Kuter D.J. Thrombotic complications of central venous catheters in cancer patients. Oncologist 9 (2004) 207-216
68. Bona R.D. Thrombotic complications of central venous catheters in cancer patients. Semin. Thromb. Hemost. 25 (1999) 147-155
69. Luciani A., Clement O., Halimi P., Goudot D., Portier F., Bassot V., et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 220 (2001) 655-660
70. Morazin F., Kriegel I., Asselain B., and Falcou M.C. Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie : un score de risque prédictif ?. Rev. Med. Interne 26 (2005) 273-279
71. Joffe H.V., and Goldhaber S.Z. Upper-extremity deep vein thrombosis. Circulation 106 (2002) 1874-1880
72. Bern M.M., Lokich J.J., Wallach S.R., Bothe A.J., Benotti P.N., Arkin C.F., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 112 (1990) 423-428
73. Monreal M., Alastrue A., Rull M., Mira X., Muxart J., Rosell R., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices prophylaxis with a low molecular weight heparin (Fragmin). Thromb. Haemost. 75 (1996) 251-253
74. Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb. Res. 109 (2003) 101-108
75. Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J. Clin. Oncol. 23 (2005) 4063-4069
76. Verso M., Agnelli G., Bertoglio S., Di Somma F.C., Paoletti F., Ageno W., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J. Clin. Oncol. 23 (2005) 4057-4062
77. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23 (2005) 2123-2129
78. Weiss R.B., Tormey D.C., Holland J.F., and Weinberg V.E. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat. Rep. 65 (1981) 677-679
79. Goodnough L.T., Saito H., Manni A., Jones P.K., and Pearson O.H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54 (1984) 1264-1268
80. Levine M.N., Gent M., Hirsh J., Arnold A., Goodyear M.D., Hryniuk W., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 318 (1988) 404-407
81. Saphner T., Tormey D.C., and Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 9 (1991) 286-294
82. Kakkar V.V., Howe C.T., Nicolaides A.N., Renney J.T., and Clarke M.B. Deep vein thrombosis of the leg. Is there a "high-risk" group?. Am. J. Surg. 120 (1970) 527-530
83. Walsh J.J., Bonnar J., and Wright F.W. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J. Obstet. Gynaecol. Br. Commonw. 81 (1974) 311-316
84. Rosenberg I.L., Evans M., and Pollock A.V. Prophylaxis of postoperative leg vine thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. BMJ 1 (1975) 649-651
85. Sue-Ling H.M., Johnston D., McMahon M.J., Philips P.R., and Davies J.A. Preoperative identification of patients at high-risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1 (1986) 1173-1176
86. Allan A., Williams J.T., Bolton J.P., and Le Quesne L.P. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br. J. Surg. 70 (1983) 172-174
87. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. JAMA 251 (1984) 2960-2966 (the multicenter trial committee)
88. Huber O., Bounameaux H., Borst F., and Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch. Surg. 127 (1992) 310-313